Disclosures Disclosure Policy Panel Member Disclosures Panel Member Disclosures by Meeting Date End User License Agreement

2020年7月13日 · Chemotherapy-induced nausea and vomiting (CINV) have been consistently demonstrated to be among the most feared adverse effects of cancer treatment. 26, 27 …

2017年7月1日 · The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Antiemesis are intended to provide an overview of the treatment principles for preventing …

2021年8月3日 · NCCN、ASCO和CSCO指南都明确提出 [2-4]：预防性用药是控制CINV的关键，止吐治疗优先应用于抗肿瘤药，选择止吐方案是基于抗肿瘤药物致吐风险等级 ...

Clinical practice guidelines published by NCCN 6 and ASCO 7 have established standard approaches to the prevention of CINV. Each set of guidelines outlines antiemetic treatment …

Numerous groups have published guidelines for the prevention and management of chemotherapy-induced nausea and vomiting (CINV). The current management of CINV, …

2024年1月18日 · DEX is effective in controlling acute and delayed CINV, with a recommended dose of 12 mg once on day 1 of chemotherapy and 8 mg once daily on days 2, 3, and 4 in …

Chemotherapy-induced nausea and vomiting (CINV) is a common toxicity that may impair the quality of life of patients with a variety of early- and end-stage malignancies. In light of recent …

Low-risk regimens induce CINV in 10% to 30%, and regimens with minimal emetogenic potential cause nausea and/or vomiting in < 10% of these patients (NCCN, 2016). The NCCN Guideline …

This session incorporated a case-study approach and interactive dialogue to provide an understanding of current antiemesis guidelines. The program was designed to illustrate ways …